Health
Concord Medical Reports Financial Results for the First Half of 2024
BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2024-09-27 19:00
4024
25 Years of Innovation and Excellence: Alma Celebrates Silver Anniversary at the Seventh Alma Academy Event in Thailand
CAESAREA, Israel, Sept. 27, 2024 /PRNewswire/ -- Alma Lasers
2024-09-27 17:00
1673
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentat...
2024-09-27 15:41
1078
Datasea Announces Fiscal Year 2024 Financial Results with Revenue 6.6x that of 2023 Primarily due to Growth of its 5G AI Business
The Total Value of 5G-AI Contracts Currently in Process Exceeds $100 MM BEIJING, Sept. 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech intelligent acoustics and 5G AI multimodal digital t...
2024-09-26 21:45
3798
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN...
2024-09-26 15:10
1367
Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management
SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ -- Mediwhale
2024-09-26 02:00
1838
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA
CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug A...
2024-09-25 21:18
1767
Bloomage's Pioneering Pilot-Scale Testing Platform Now Fully Operational, Ushering in New Era of Open Innovation
PARSIPPANY, N.J., Sept. 25, 2024 /PRNewswire/ -- Bloomage, a global leader specializing in hyaluronic acid and other bioactive substance innovations, has announced the completion of its new pilot-scale testing platform. With the pharmaceutical-grade pilot testing wing now fully operational, this ...
2024-09-25 21:00
1133
Flat Medical Strengthens Market Leadership with Acquisition of InjeQ Assets, Including FDA-Designated Breakthrough Device IQ-Tip®
TAIPEI, Sept. 25, 2024 /PRNewswire/ -- Flat Medical, a leading innovator in medical technology, today announced its acquisition of key assets from InjeQ, including the FDA-designated breakthrough device, IQ-Tip®. This strategic move bolsters Flat Medical's leadership position in the medical devic...
2024-09-25 20:00
1480
Samsung Biologics launches development platforms for enhanced therapeutic efficacy
* Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiChargeTM – at BioProcess International 2024 * New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea, Sept. 25, 2024 /PRNewswire...
2024-09-25 19:00
1291
Bestqool Pro Series Iteration: Upgraded Design for Enhanced User Experience
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Bestqool, a leading red light therapy
industry company, proudly presents the newest iteration of itsPro Series
2024-09-24 21:00
832
Noul Demonstrates 'Expert-Level' AI Diagnostic Performance in Europe… Results from Spain's Carlos III Health Institute
* Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis * Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92% YONGIN, South Korea, Sept. 24, 2024 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim, hereafter referred to as "Noul") has proven the expe...
2024-09-24 21:00
931
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced the completion of its Series B2 ...
2024-09-24 21:00
1650
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, XtalPi will offer commercial licenses with flexible terms f...
2024-09-24 21:00
3128
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery
CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™ ), announced today that it has entered into a strategic collaboration with Alkyon Therapeutics, Inc. (AlkyonTx), aSan Diego-based biotechnology ...
2024-09-24 20:00
851
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024
SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- On September 14, 2024, BioCity presented interim clinical results on the safety and efficacy of its first-in-class antibody-drug conjugate (ADC) BC3195 targeting CDH3 (P-Cadherin) in a Phase I clinical trial at the European Society for Medical Oncology (ES...
2024-09-23 17:40
1739
WuXi Biologics Included in Hang Seng ESG 50 Index
HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this...
2024-09-23 17:30
1167
Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease Treatments
BEIJING, Sept. 23, 2024 /PRNewswire/ -- Professor Luo Min, Doctor of Medicine (MD), from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, was recently appointed as the Chairman of the National Association of Health Industry and Enterprise Management (NAHIE...
2024-09-23 15:06
1098
Gymera Reveal A Breakthrough in Smart Home Fitness and Elderly Wellness Solution at Hong Kong Global Sources Consumer Electronics Show 2024
SHENZHEN, China, Sept. 21, 2024 /PRNewswire/ -- In today's fast-paced world, maintaining health and vitality has become increasingly important, especially in home fitness and eldercare scenarios. Gymera proudly introduces the MA-001, a full-featured smart fitness mirror that perfectly integrates ...
2024-09-21 18:32
3593
Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results
YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its unaudited ...
2024-09-21 05:30
6896
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5634
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
2024-11-08 20:11
5568
HOIANA RESORT & GOLF LAUNCHES PREMIUM HOIANA PICKLEBALL COURT
2024-11-08 00:18
5520
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5403